• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Precigen Inc. (Amendment)

    1/24/22 10:04:58 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PGEN alert in real time by email
    SC 13G/A 1 tm224161d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

     

    (Amendment No. 3)*

     

     

    Precigen, Inc.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    46122T102
    (CUSIP Number)
     
    31 December 2021
    (Date of Event Which Requires Filing of the Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o       Rule 13d-1(b)

    x       Rule 13d-1(c)

    o       Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

      

    Cusip No. 46122T102 13G Page 2 of 8 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

    Ares Trading SA

         

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) o

    (b) o

    3.

    SEC USE ONLY

     

            

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Switzerland

         

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    SOLE VOTING POWER

    20,647,1521

         

    6.

     

    SHARED VOTING POWER

    0

         

    7.

     

    SOLE DISPOSITIVE POWER

    20,647,1521 

         

    8.

     

    SHARED DISPOSITIVE POWER

    0 

         

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    20,647,1521

         

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%2

         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    CO 

         

     

     

    1 The record holder of the securities covered by this Schedule 13G is Ares Trading SA.

     

    Ares Trading SA is a dominantly controlled subsidiary of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.

     

    Merck Serono SA, Coinsins, Switzerland is a wholly owned indirect subsidiary of Merck KGaA, Darmstadt, Germany.

     

    Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 30) and the beneficiary of the two companies.

     

    Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany and Merck KGaA, Darmstadt, Germany may be deemed to possess sole voting and dispositive power with respect to the securities held of record by Ares Trading SA.

     

    2 This percentage is based upon a denominator of 206,738,499 shares of Common Stock outstanding as of October 31, 2021 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 08, 2021.

     

     

     

     

    Cusip No. 46122T102 13G Page 3 of 8 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

    Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany

         

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) o

    (b) o

    3.

    SEC USE ONLY

     

            

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Switzerland

         

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    SOLE VOTING POWER

    20,647,1523

         

    6.

     

    SHARED VOTING POWER

    0

         

    7.

     

    SOLE DISPOSITIVE POWER

    20,647,1523 

         

    8.

     

    SHARED DISPOSITIVE POWER

    0 

         

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    20,647,1523

         

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%4

         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    CO 

         

     

     

    3 The record holder of the securities covered by this Schedule 13G is Ares Trading SA.

     

    Ares Trading SA is a dominantly controlled subsidiary of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.

     

    Merck Serono SA, Coinsins, Switzerland is a wholly owned indirect subsidiary of Merck KGaA, Darmstadt, Germany.

     

    Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 30) and the beneficiary of the two companies.

     

    Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany and Merck KGaA, Darmstadt, Germany may be deemed to possess sole voting and dispositive power with respect to the securities held of record by Ares Trading SA.

     

    4 This percentage is based upon a denominator of 206,738,499 shares of Common Stock outstanding as of October 31, 2021 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 08, 2021.

     

     

     

     

    Cusip No. 46122T102 13G Page 4 of 8 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

    Merck KGaA, Darmstadt, Germany

         

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) o

    (b) o

    3.

    SEC USE ONLY

     

            

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Germany

         

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    SOLE VOTING POWER

    20,647,1525

         

    6.

     

    SHARED VOTING POWER

    0

         

    7.

     

    SOLE DISPOSITIVE POWER

    20,647,1525 

         

    8.

     

    SHARED DISPOSITIVE POWER

    0 

         

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    20,647,1525

         

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%6

         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    CO 

         

     

     

    5 The record holder of the securities covered by this Schedule 13G is Ares Trading SA.

     

    Ares Trading SA is a dominantly controlled subsidiary of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.

     

    Merck Serono SA, Coinsins, Switzerland is a wholly owned indirect subsidiary of Merck KGaA, Darmstadt, Germany.

     

    Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 30) and the beneficiary of the two companies.

     

    Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany and Merck KGaA, Darmstadt, Germany may be deemed to possess sole voting and dispositive power with respect to the securities held of record by Ares Trading SA.

     

    6 This percentage is based upon a denominator of 206,738,499 shares of Common Stock outstanding as of October 31, 2021 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 08, 2021.

     

     

     

      

    Cusip No. 46122T102 13G Page 5 of 8 Pages

     

     

    Item 1(a). Name of Issuer:
      Precigen, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
      20374 Seneca Meadows Parkway
      Germantown, Maryland, 20876
       
    Item 2(a). Name of Person Filing:
     

    This Schedule 13G is being filed by each of the following persons (each, a “Reporting Person” and together, the “Reporting Persons”):

     

    Ares Trading SA

    Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany

    Merck KGaA, Darmstadt, Germany

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k)(l) of the Securities Exchange Act of 1934, as amended.

       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
     

    Ares Trading SA: Zone Industrielle de l’Outriettaz, 1170 Aubonne, Switzerland

    Merck Serono SA: Zone Industrielle, 1267 Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany

    Merck KGaA: Frankfurter Strasse 250, 64293 Darmstadt, Germany

       
    Item 2(c). Citizenship:
      The Reporting Persons Ares Trading SA and Merck Serono SA Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany are organized in Switzerland. The Reporting Person Merck KGaA is organized in Darmstadt, Germany.  
       
    Item 2(d). Title of Class of Securities:
      Common Stock, no par value per share
       
    Item 2(e). CUSIP Number:
      46122T102 
       
    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
     

     

    Not applicable

      (a) o Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) o Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) o An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

     

     

      

    Cusip No. 46122T102 13G Page 6 of 8 Pages

     

     

    Item 4. Ownership:
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: 20,647,1527
         
      (b) Percent of class: 9.99%8
         
      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote: 20,647,1527
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 20,647,1527
        (iv) Shared power to dispose or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o.
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      Not applicable 
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
      Not applicable 
       
    Item 8. Identification and Classification of Members of the Group:
      Not applicable
       
    Item 9. Notice of Dissolution of Group:
      Not applicable
       
    Item 10. Certifications:
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

      

     

    7 The record holder of the securities covered by this Schedule 13G is Ares Trading SA.

     

    Ares Trading SA is a dominantly controlled subsidiary of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.

     

    Merck Serono SA, Coinsins, Switzerland is a wholly owned indirect subsidiary of Merck KGaA, Darmstadt, Germany.

     

    Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 30) and the beneficiary of the two companies.

     

    Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany and Merck KGaA, Darmstadt, Germany may be deemed to possess sole voting and dispositive power with respect to the securities held of record by Ares Trading SA.

     

    8 This percentage is based upon a denominator of 206,738,499 shares of Common Stock outstanding as of October 31, 2021 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 08, 2021.

     

     

     

     

    Cusip No. 46122T102 13G  

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    ARES TRADING SA  

    ARES TRADING SA

     

    Date: January 20, 2022   Date: January 20, 2022
             
             
    By: /s/ Cedric Hyde   By: /s/ Florence Jolidon
             
    Name: Cedric Hyde   Name: Florence Jolidon
             
    Title: CFO   Title: Finance Manager

     

     

    MERCK SERONO SA, COINSINS, SWITZERLAND, AN AFFILIATE OF MERCK KGAA, DARMSTADT, GERMANY  

    MERCK SERONO SA, COINSINS, SWITZERLAND, AN AFFILIATE OF MERCK KGAA, DARMSTADT, GERMANY

     

    Date:  January 20, 2022   Date: January 20, 2022
             
             
    By: /s/ Cecric Hyde   By: /s/ Tearaboth Te
             
    Name: Cedric Hyde   Name: Tearaboth Te
             
    Title: CFO   Title: Treasury Director

      

     

    MERCK KGAA, DARMSTADT, GERMANY  

    MERCK KGAA, DARMSTADT, GERMANY

     

    Date: January 20, 2022   Date: January 20, 2022
             
             
    By: /s/ Jens Eckhardt   By: /s/ Tobias Greven
             
    Name: Jens Eckhardt   Name: Tobias Greven
             
    Title: Head of Legal HC BD, Alliance Mgt, GMS & Governance   Title: Head of Group Legal Services

      

     

     

      

    Cusip No. 46122T102 13G  

     

    EXHIBIT INDEX

     

    Exhibit 99.1 Joint Filing Agreement, dated January 7, 2019, by and between Ares Trading SA, Merck Serono SA, Coinsins, Switzerland, and Merck KGaA, Darmstadt, Germany.

     

     

     

     

     

     

    Get the next $PGEN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PGEN

    DatePrice TargetRatingAnalyst
    3/22/2024Neutral → Underweight
    JP Morgan
    5/23/2023Neutral
    JP Morgan
    11/18/2022$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Agee Nancy H converted options into 126,760 shares, increasing direct ownership by 253% to 176,836 units (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      7/7/25 4:26:36 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Tennant Phil

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      6/27/25 4:16:22 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Shah Rutul R

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      6/27/25 4:13:05 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precigen Reports First Quarter 2025 Financial Results and Business Updates

      PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

      5/14/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Reports Full Year 2024 Financial Results and Business Updates

      FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory MedicinePRGN-2012 treatment demonstrated durable complete responses with median duration of response of two years, with some complete responders surgery-free beyond three years as of August 28, 2024 data cutoffCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launchCompany ended 2024 with $97.9 million in cash, cash equivalents, and investments, extending i

      3/19/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Precigen downgraded by JP Morgan

      JP Morgan downgraded Precigen from Neutral to Underweight

      3/22/24 7:52:12 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Precigen

      JP Morgan initiated coverage of Precigen with a rating of Neutral

      5/23/23 7:32:58 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Precigen with a new price target

      Cantor Fitzgerald initiated coverage of Precigen with a rating of Overweight and set a new price target of $7.00

      11/18/22 7:56:19 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    SEC Filings

    See more
    • Precigen Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - PRECIGEN, INC. (0001356090) (Filer)

      6/30/25 4:11:29 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Precigen Inc.

      DEFA14A - PRECIGEN, INC. (0001356090) (Filer)

      5/16/25 4:05:03 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Precigen Inc.

      DEF 14A - PRECIGEN, INC. (0001356090) (Filer)

      5/16/25 4:03:40 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Precigen Inc.

      SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

      8/13/24 4:05:10 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Precigen Inc. (Amendment)

      SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

      5/3/24 8:01:15 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Precigen Inc. (Amendment)

      SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)

      2/27/24 1:48:40 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Financials

    Live finance-specific insights

    See more
    • Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

      GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

      3/13/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

      GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering

      12/27/24 9:00:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

      GERMANTOWN, Md., Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357

      8/9/24 8:00:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Precigen Reports First Quarter 2025 Financial Results and Business Updates

      PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

      5/14/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

      –  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden

      7/23/24 8:01:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, IP Affairs Perez Jeffrey Thomas bought $50,000 worth of shares (58,823 units at $0.85), increasing direct ownership by 9% to 743,097 units (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      8/13/24 5:09:47 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kirk Randal J bought $19,999,999 worth of shares (23,529,411 units at $0.85) (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      8/13/24 4:15:11 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kirk Randal J bought $136,327 worth of shares (96,686 units at $1.41) (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      12/29/23 7:30:15 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care